U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H32O6
Molecular Weight 404.4966
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Hydrocortisone Acetate

SMILES

CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C

InChI

InChIKey=ALEXXDVDDISNDU-JZYPGELDSA-N
InChI=1S/C23H32O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-18,20,26,28H,4-9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H32O6
Molecular Weight 404.4966
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008697s032_33lbl.pdf

Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). Hydrocortisone is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

CNS Activity

Curator's Comment: shown in dogs

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

1952
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

1952
Palliative
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

1952
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

1952
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
305 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1162 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.82 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The stress hormone, cortisol, synergizes with HIV-1 gp-120 to induce apoptosis of normal human peripheral blood mononuclear cells.
2000 Nov
Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
2001 Feb
Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3',5'-monophosphate and p53 activation in immortalized human granulosa cells: involvement of Bcl-2.
2001 Feb
Regulation of phosphate uptake in primary cultured rabbit renal proximal tubule cells by glucocorticoids: evidence for nongenomic as well as genomic mechanisms.
2001 Feb
Plasma adrenocorticotropin and cortisol concentrations during acute hypoxemia after a reversible period of adverse intrauterine conditions in the ovine fetus during late gestation.
2001 Feb
PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells.
2001 Feb
Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report.
2001 Feb
Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.
2001 Feb
Relationship functioning and home and work demands predict individual differences in diurnal cortisol patterns in women.
2001 Feb
Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results.
2001 Feb
Green fluorescent protein mutant as label in homogeneous assays for biomolecules.
2001 Feb 1
Net amino acid flux across the fetal liver and placenta during spontaneous ovine parturition.
2001 Jan
Effects of cortisol on chloride cells in the gill epithelium of Japanese eel, Anguilla japonica.
2001 Jan
Monohydroxylation and esterification as determinants of the effects of cis- and trans-9-octadecenoic acids on the permeation of hydrocortisone and 5-fluorouracil across hairless mouse skin in vitro.
2001 Jan 16
Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney.
2001 Jan 22
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Many Hydrocortisone products are used topically https://www.drugs.com/pro/hydrocortisone.html
The initial dosage of CORTEF (Hydrocortisone) Tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated.
Route of Administration: Oral
Hydrocortisone concentration-dependently inhibited the current induced by 3 x 10(-5) M ACh with a half maximum inhibitory concentration (IC50) of 2.1 x 10(-4) M (in rats).
Substance Class Chemical
Created
by admin
on Wed Apr 02 17:59:18 GMT 2025
Edited
by admin
on Wed Apr 02 17:59:18 GMT 2025
Record UNII
3X7931PO74
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARMOL HC COMPONENT HYDROCORTISONE ACETATE
Preferred Name English
Hydrocortisone Acetate
EP   GREEN BOOK   INCI   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INCI  
Official Name English
DRICORT
Brand Name English
HYDROCORTISONE ACETATE [EP IMPURITY]
Common Name English
HYDROCORTISONE ACETATE [ORANGE BOOK]
Common Name English
HYDROCORTISONI ACETAS [WHO-IP LATIN]
Common Name English
HYDROCORTISONE IMPURITY C [EP IMPURITY]
Common Name English
PREDNISOLONE ACETATE IMPURITY A [EP]
Common Name English
HYDROCORTISONE HYDROGEN SUCCINATE IMPURITY B [EP IMPURITY]
Common Name English
EPIFOAM COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [MART.]
Common Name English
TERRA-CORTRIL COMPONENT HYDROCORTISONE ACETATE
Common Name English
PRAMOSONE COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [USP-RS]
Common Name English
HEMSOL-HC
Brand Name English
HYDROCORTISONE ACETATE [USP MONOGRAPH]
Common Name English
COR-OTICIN COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE 21-ACETATE
MI  
Common Name English
ORABASE HCA
Brand Name English
NSC-741
Code English
CORTIFOAM
Brand Name English
NEO-CORTEF COMPONENT HYDROCORTISONE ACETATE
Common Name English
COLY-MYCIN S COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [GREEN BOOK]
Common Name English
MICORT-HC
Brand Name English
PREGN-4-ENE-3,20-DIONE, 21-(ACETYLOXY)-11,17-DIHYDROXY-, (11.BETA.)-
Systematic Name English
CHLOROMYCETIN HYDROCORTISONE COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [WHO-IP]
Common Name English
Hydrocortisone acetate [WHO-DD]
Common Name English
OPHTHOCORT COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [VANDF]
Common Name English
HYDROCORTISONE 21-ACETATE [MI]
Common Name English
HYDROCORTISONE SODIUM SUCCINATE IMPURITY B [EP IMPURITY]
Common Name English
U-CORT COMPONENT HYDROCORTISONE ACETATE
Common Name English
PROCTOFOAM HC COMPONENT HYDROCORTISONE ACETATE
Common Name English
CORTEF ACETATE
Brand Name English
HYDROCORTISONE ACETATE [EP MONOGRAPH]
Common Name English
Cortisol 21-acetate
Common Name English
HYDROCORTISONE ACETATE [JAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
FDA ORPHAN DRUG 568616
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
Code System Code Type Description
DRUG CENTRAL
4213
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
DAILYMED
3X7931PO74
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
NSC
741
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
RXCUI
27197
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY RxNorm
CAS
50-03-3
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
RS_ITEM_NUM
1317007
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
MESH
C021650
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
WIKIPEDIA
Hydrocortisone acetate
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
EVMPD
SUB02562MIG
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
HYDROCORTISONE ACETATE
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS; very slightly soluble in ether R. Category: Adrenocortical steroid. Storage: Hydrocortisone acetate should be kept in a well-closed container, protected from light.Additional information: Hydrocortisone acetate melts at about 220?C with decomposition. Definition: Hydrocortisone acetate contains not less than 97.0% and not more than 102.0% of C23H32O6, calculated with reference to the dried substance.
ECHA (EC/EINECS)
200-004-4
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
DRUG BANK
DB14539
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
NCI_THESAURUS
C61785
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
MERCK INDEX
m6094
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY Merck Index
FDA UNII
3X7931PO74
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
SMS_ID
100000092260
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
ChEMBL
CHEMBL1091
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
EPA CompTox
DTXSID0048686
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
CHEBI
17609
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
PUBCHEM
5744
Created by admin on Wed Apr 02 17:59:19 GMT 2025 , Edited by admin on Wed Apr 02 17:59:19 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY